The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
The Apolipoprotein ε4 Allele Determines Prognosis and the Effect on Prognosis of Simvastatin in Survivors of Myocardial Infarction: A Substudy of the Scandinavian Simvastatin Survival Study
Open accessAbstract
Background —Carriers of the ε4 allele of the apolipoprotein E gene are at a higher risk of coronary heart disease than individuals with other genotypes. We examined whether the risk of death or a major coronary event in survivors of myocardial infarction depended on apolipoprotein E genotype and whether the benefits of treatment with simvastatin differed between genotypes. Methods and Results —Cox proportional hazards models were used to analyze 5.5 years of follow-up data from 966 Danish and Finnish myocardial infarction survivors enrolled in the Scandinavian Simvastatin Survival Study. A total of 16% of the 166 ε4 carriers in the placebo group died compared with 9% of the 312 patients without the allele, which corresponds to a mortality risk ratio of 1.8 (95% confidence interval, 1.1 to 3.1). The risk ratio was unaffected by considerations of sex, age, concurrent angina, diabetes, smoking, and serum lipids in multivariate analyses. Simvastatin treatment reduced the mortality risk to 0.33 (95% confidence interval, 0.16 to 0.69) in ε4 carriers and to 0.66 (95% confidence interval, 0.35 to 1.24) in other patients ( P =0.23 for treatment by genotype interaction). Apolipoprotein E genotype did not predict the risk of a major coronary event. Baseline serum levels of lipoprotein(a) also predicted mortality risk and could be combined with ε4-carrier status to define 3 groups of patients with different prognoses and benefits from treatment. Conclusions —Myocardial infarction survivors with the ε4 allele have a nearly 2-fold increased risk of dying compared with other patients, and the excess mortality can be abolished by treatment with simvastatin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Apolipoprotein E: Cholesterol Transport Protein with Expanding Role in Cell Biology
Mahley, R. W. (1988) · Science · doi:10.1126/science.3283935 · Cited by 4,028
Apolipoprotein E polymorphism and atherosclerosis.
Davignon, J., Gregg, R. E., & Sing, C. F. (1988) · Arteriosclerosis: An Official Journal of the American Heart Association, Inc. · doi:10.1161/01.atv.8.1.1 · Cited by 1,981
Apolipoprotein E: Structure-Function Relationships
Weisgraber, K. H. (1994) · Advances in Protein Chemistry · doi:10.1016/s0065-3233(08)60642-7 · Cited by 830
Apolipoprotein E polymorphism in health and disease
Utermann, G. (1987) · American Heart Journal · doi:10.1016/0002-8703(87)90610-7 · Cited by 389
Cited by
Pharmacogenomics — Drug Disposition, Drug Targets, and Side Effects
Evans, W. E., & McLeod, H. L. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020526 · Cited by 1,769
Apolipoprotein E Polymorphism and Cardiovascular Disease: A HuGE Review
Eichner, J. E. (2002) · American Journal of Epidemiology · doi:10.1093/aje/155.6.487 · Cited by 796
Association of apolipoprotein E genotypes with lipid levels and coronary risk
Bennet, A. M., Di Angelantonio, E., Ye, Z., Wensley, F., Dahlin, A., Ahlbom, A., Keavney, B., Collins, R., Wiman, B., de Faire, U., et al. (2007) · JAMA · doi:10.1001/jama.298.11.1300 · Cited by 794
Meta-Analysis: Apolipoprotein E Genotypes and Risk for Coronary Heart Disease
Song, Y., Stampfer, M. J., & Liu, S. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-2-200407200-00013 · Cited by 528
Nabel, E. G. (2003) · New England Journal of Medicine · doi:10.1056/nejmra035098 · Cited by 431
Metadata
- Authors
- Gerdes, L. U., Gerdes, C., Kervinen, K., Savolainen, M., Klausen, I. C., Hansen, P. S., Kesäniemi, Y. A., & Færgeman, O.
- Venue
- Circulation
- Published
- 2000-03-28
- Volume
- 101
- Issue
- 12
- Pages
- 1366-1371
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W1996359690
- Cited by
- 236
- References
- 4
- FWCI
- 20.14
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Apolipoprotein ε4 Allele Determines Prognosis and the Effect on Prognosis of Simvastatin in Survivors of Myocardial Infarction: A Substudy of the Scandinavian Simvastatin Survival Study. https://app.cochat.ai/papers/10.1161/01.cir.101.12.1366
- The paper
- Gerdes, L. U., Gerdes, C., Kervinen, K., Savolainen, M., Klausen, I. C., Hansen, P. S., Kesäniemi, Y. A., & Færgeman, O. (2000). The Apolipoprotein ε4 Allele Determines Prognosis and the Effect on Prognosis of Simvastatin in Survivors of Myocardial Infarction: A Substudy of the Scandinavian Simvastatin Survival Study. Circulation. https://doi.org/10.1161/01.cir.101.12.1366
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.